Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Strategies to optimize management in rhabdomyosarcoma (RMS) include risk stratification to assign therapy aiming to minimize treatment morbidity yet improve outcomes. This analysis evaluated the relationship between complete metabolic response (CMR) as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG‐PET) imaging and event‐free survival (EFS) in intermediate‐risk (IR) and high‐risk (HR) RMS patients.

[1]  M. Scorsetti,et al.  Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging. , 2020, The British journal of radiology.

[2]  James R. Anderson,et al.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.

[3]  James R. Anderson,et al.  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. H. van der Lee,et al.  Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study , 2018, Cancer.

[5]  Steve Y. Cho,et al.  Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. , 2018, Radiology.

[6]  W. Reddick,et al.  18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma , 2018, Journal of Nuclear Medicine.

[7]  K. McHugh,et al.  Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). , 2017, European journal of cancer.

[8]  James R. Anderson,et al.  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. McHugh,et al.  An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review , 2015, BMJ Open.

[10]  H. Schoder,et al.  Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography. , 2014, International journal of radiation oncology, biology, physics.

[11]  Allen R. Chen,et al.  Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  James R. Anderson,et al.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  U. Harmenberg,et al.  Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma , 2014, BMC Cancer.

[14]  Qiyong Ding,et al.  PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). , 2014, Journal of thoracic disease.

[15]  Byung Il Kim,et al.  Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18 F-FDG PET/CT and MRI , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  James R. Anderson,et al.  Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group. , 2014, European journal of cancer.

[17]  J. Choi,et al.  Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters , 2014, Skeletal Radiology.

[18]  F. O’Sullivan,et al.  Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome. , 2014, The Journal of bone and joint surgery. American volume.

[19]  Soo-Yong Lee,et al.  Comparison of (18)F-FDG PET/CT and (99 m)Tc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma , 2013, Skeletal Radiology.

[20]  D. Jeon,et al.  Combination of 18F-FDG PET/CT and Diffusion-Weighted MR Imaging as a Predictor of Histologic Response to Neoadjuvant Chemotherapy: Preliminary Results in Osteosarcoma , 2013, The Journal of Nuclear Medicine.

[21]  Sara M. Federico,et al.  Comparison of PET–CT and conventional imaging in staging pediatric rhabdomyosarcoma , 2013, Pediatric blood & cancer.

[22]  S. Spunt,et al.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas , 2013, Pediatric blood & cancer.

[23]  C. Leux,et al.  18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas , 2012, Nuclear medicine communications.

[24]  S. Dry,et al.  18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy , 2012, Clinical Cancer Research.

[25]  H. Schöder,et al.  Positron Emission Tomography (PET) Response to Initial Chemotherapy and Radiation Therapy (RT) Predicts Local Control in Rhabdomyosarcoma , 2011 .

[26]  C. Freeman,et al.  Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas , 2011, Journal of surgical oncology.

[27]  J. Eary,et al.  [F‐18]‐fluorodeoxy‐D‐glucose–positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults , 2009, Cancer.

[28]  Joel S. Karp,et al.  Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience , 2009, Journal of Nuclear Medicine.

[29]  Roland L Bassett,et al.  18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma , 2009, Journal of Nuclear Medicine.

[30]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  James R. Anderson,et al.  Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Hesseling,et al.  PROGNOSTIC VALUE OF DAY 14 BLAST PERCENTAGE AND THE ABSOLUTE BLAST INDEX IN BONE MARROW OF CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA , 2001, Pediatric hematology and oncology.

[33]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[34]  A. Huvos,et al.  The Histological Response to Chemotherapy as a Predictor of the Oncological Outcome of Operative Treatment of Ewing Sarcoma* , 1998, The Journal of bone and joint surgery. American volume.

[35]  F. Behm,et al.  Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  渡辺 誠,et al.  ^ F-Fluorodeoxy-D-glucose と Positron Emission Tomography を用いたガム咀嚼時の咀嚼筋および舌筋活動測定 , 1997 .

[37]  S. Ferrari,et al.  Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B Sundell,et al.  Soft-tissue sarcomas. , 1979, British medical journal.

[39]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[40]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[41]  M. Gelfand,et al.  Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: Sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging—A prospective trial , 2017, Cancer.

[42]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  L. Ries,et al.  Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. , 1999 .

[44]  H. Sather,et al.  Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. , 1990, Medical and pediatric oncology.

[45]  G. Rosen,et al.  Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors. , 1984, Cancer investigation.

[46]  D.,et al.  Regression Models and Life-Tables , 2022 .